Metropolitan Life Insurance CO Krystal Biotech, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$108.01 - $179.35 $11,881 - $19,728	-110 Reduced 8.83%	1,136 $202,000
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $8,246 - $9,896	76 Added 6.5%	1,246 $144,000
Q2 2023 Aug 10, 2023	BUY	$78.48 - $130.32 $3,374 - $5,603	43 Added 3.82%	1,170 $137,000
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $11,292 - $13,146	-156 Reduced 12.16%	1,127 $90,000
Q4 2022 Jun 14, 2023	BUY	$63.14 - $79.9 $9,849 - $12,464	156 Added 13.84%	1,283 $102 Million
Q3 2022 Jun 14, 2023	BUY	$64.85 - $82.4 $10,116 - $12,854	156 Added 13.84%	1,283 $89.4 Million
Q2 2022 Jun 20, 2023	BUY	$48.93 - $73.47 $7,633 - $11,461	156 Added 13.84%	1,283 $84,000
Q1 2022 Jun 20, 2023	BUY	$51.99 - $72.11 $8,110 - $11,249	156 Added 13.84%	1,283 $85,000
Q1 2022 Mar 30, 2023	SELL	$51.99 - $72.11 $182,120 - $252,601	-3,503 Reduced 73.19%	1,283 $85,000
Q1 2022 May 12, 2022	SELL	$51.99 - $72.11 $182,120 - $252,601	-3,503 Reduced 73.19%	1,283 $85,000
Q4 2021 Jun 21, 2023	BUY	$39.81 - $88.24 $145,664 - $322,870	3,659 Added 324.67%	4,786 $334,000
Q3 2021 Jun 21, 2023	BUY	$52.01 - $71.77 $190,304 - $262,606	3,659 Added 324.67%	4,786 $249,000
Q3 2021 Mar 30, 2023	BUY	$52.01 - $71.77 $4,732 - $6,531	91 Added 1.94%	4,786 $249,000
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $4,732 - $6,531	91 Added 1.94%	4,786 $250,000
Q2 2021 Jun 21, 2023	BUY	$62.14 - $81.82 $221,715 - $291,933	3,568 Added 316.59%	4,695 $319,000
Q2 2021 Mar 30, 2023	BUY	$62.14 - $81.82 $19,325 - $25,446	311 Added 7.09%	4,695 $319,000
Q2 2021 Aug 16, 2021	BUY	$62.14 - $81.82 $291,498 - $383,817	4,691 Added 117275.0%	4,695 $319,000
Q1 2021 Jun 26, 2023	BUY	$59.42 - $85.46 $193,530 - $278,343	3,257 Added 289.0%	4,384 $338 Million
Q1 2021 Mar 30, 2023	SELL	$59.42 - $85.46 $14,141 - $20,339	-238 Reduced 5.15%	4,384 $337,000
Q1 2021 May 14, 2021	SELL	$59.42 - $85.46 $274,401 - $394,654	-4,618 Reduced 99.91%	4 $338,000
Q4 2020 Jun 22, 2023	BUY	$40.64 - $61.38 $142,036 - $214,523	3,495 Added 310.12%	4,622 $277,000
Q3 2020 Jun 26, 2023	BUY	$37.76 - $48.49 $131,971 - $169,472	3,495 Added 310.12%	4,622 $198,000
Q2 2020 Jun 26, 2023	BUY	$37.03 - $60.0 $129,419 - $209,700	3,495 Added 310.12%	4,622 $191,000
Q2 2020 Mar 30, 2023	BUY	$37.03 - $60.0 $50,360 - $81,600	1,360 Added 41.69%	4,622 $191,000
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $50,360 - $81,600	1,360 Added 41.69%	4,622 $191,000
Q1 2020 Jul 12, 2023	BUY	$35.02 - $65.64 $74,767 - $140,141	2,135 Added 189.44%	3,262 $141,000
Q4 2019 Jul 12, 2023	BUY	$33.17 - $65.23 $70,817 - $139,266	2,135 Added 189.44%	3,262 $180,000
Q3 2019 Jul 12, 2023	BUY	$34.72 - $51.3 $74,127 - $109,525	2,135 Added 189.44%	3,262 $113,000
Q3 2019 Mar 30, 2023	BUY	$34.72 - $51.3 $68,710 - $101,522	1,979 Added 154.25%	3,262 $113,000
Q3 2019 Nov 14, 2019	BUY	$34.72 - $51.3 $113,256 - $167,340	3,262 New	3,262 $113,000
Q2 2019 Jul 12, 2023	SELL	$27.2 - $41.2 $11,315 - $17,139	-416 Reduced 36.91%	711 $28.6 Million

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

Black Rock Inc. New York, NY

3.95M
Shares

$720 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

2.85M
Shares

$519 Million
0.01% of portfolio
Avoro Capital Advisors LLC New York, NY

2.62M
Shares

$478 Million
7.18% of portfolio
State Street Corp Boston, MA

1.45M
Shares

$265 Million
0.01% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

988K
Shares

$180 Million
9.67% of portfolio

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.68B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account